Document Type : Research articles


1 Department of General Surgery, Erciyes University Medical Faculty, Melikgazi, Kayseri, Turkey

2 Department of Surgical Oncology, Erciyes University Medical Faculty, Melikgazi, Kayseri, Turkey

3 Department of Pathology, Erciyes University Medical Faculty, Melikgazi, Kayseri, Turkey


Background: A majority of colorectal neoplasms are adenocarcinomas; however, there is a small percentage of tumors from other histological cell lines.
Methods: A total of 1100 patients were applied for surgical treatment due to colorectal cancer at a general surgical clinic between 2010 and 2020. The selected patients were divided into four groups of Diffuse large B-cell lymphoma (DLBCL), Malignant melanoma (MM), Medullary carcinoma (MC), and Neuroendocrine tumor (NET). Following that, clinicopathological data of patients and their survival periods have been compared in this study.
Results: A total of 20 patients were included in this study and were divided into the DLBCL (n=5), MM (n=4), MC (n=3), and NET (n=8) groups. The emergency application rate (60%) was the highest in the DLBCL group (P=0.004). The mean age of the patients was above 50 years in all groups, and there was no difference among groups in this regard (P=0.966). The mean tumor diameter values were 8, 6.55, 5.4, and 3.75 cm, respectively (P=0.73) in the groups. Furthermore, the numbers of lymph nodes dissected were 13, 14.5, 19, and 19, respectively (P=0.373), and the numbers of metastatic lymph nodes were determined at 0 ,1.5, 0, and 0.5, respectively (P=0.188). The survival rate was significantly the shortest in the MM group, and the longest survival rate was noted in the NET group (15.625, 8.5, 20, 40.857, respectively; P=0.001).
Conclusion: Although clinicopathological features and postoperative follow-up results were similar, there were differences in the survival rates among patients. Malignant melanoma histopathological type had a worse prognosis than the other tumors.


  1. Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XL. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011;34(6):573-580.doi: 10.1097/COC.0b013e3181fe41ed.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.doi: 10.3322/caac.21442.
  3. [pa´gina en Internet]. Bethesda.Maryland: US National Institutes of Health. 2013.
  4. Terada T. Histopathologic study of the rectum in 1,464 consecutive rectal specimens in a single Japanese hospital: II. malignant lesions. Int J Clin Exp Pathol. 2013;6(3):385-394. PMID: 23412998.
  5. Errasti Alustiza J, Espín Basany E, Reina Duarte A. Rare tumors of the rectum. Narrative review. Cir Esp. 2014;92(9):579-588.doi: 10.1016/j.ciresp.2013.06.019. PMID: 24629769.
  6. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22(2):183-189.doi: 10.1007/s00384-006-0145-2. PMID: 16845516.
  7. Cuffy M, Abir F, Longo WE. Management of less common tumors of the colon, rectum, and anus. Clin Colorectal Cancer. 2006;5(5):327-337.doi: 10.3816/CCC.2006.n.002 . PMID: 16512991.
  8. SayhanSevil, KAHRAMAN, Dudu Solakoglu. Pathologic Features of Colorectal Carcinomas. In: Colon Polyps and Colorectal Cancer. Springer Cham.2021:455-480.
  9. Dere Y , Dere Ö , Ekmekçi S , Çelik S , İlhan Çelik Ö , Nazlı O, et al . Kolorektal Karsinomlardaki Histopatolojik Özellikler. MMJ. 2018; 5(2): 1-4.
  10.  Mlecnik B, Tosolini M, Kirilovsky A,   Berger A,  Bindea G,  Meatchi T,  Bruneval P, Trajanoski Z,  Fridman WH,  Pagès F,  Galon J,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-618.doi: 10.1200/JCO.2010.30.5425 . PMID: 21245428.
  11. Shields CJ, Tiret E, Winter DC. Carcinoid tumors of the rectum. A multi-institutional international collaboration Ann Surg. 2010;252:750–5.doi: 10.1097/SLA.0b013e3181fb8df6 . PMID: 21037430.
  12. Pavel M, Baudin E, Couvelard A, Krenning E, O¨ berg K Steinmu¨ ller T, et al. ENETS consensus guidelines for de management of patients with liver metastases fro digestive neuroendocrine neoplasms of foregut, midgut, hingut, and unknown primary. neuroendocrinology. 2012;95:157–76.doi: 10.1159/000335597.
  13. Fan CW, Changchien Cr, Wang JY, Chen JS, Hsu KC, Tang R, et al. Primary colorectallymphoma.DisColonRectum.2005;43:1277-1282.doi:10.1007/BF02237436.
  14.  N. Doolabh, T. Anthony, C. Simmang, S. Bieligk, E. Lee, P. Huber, R. Hughes, et al. Primary colonic lymphoma. J Surg Oncol 2000; 74: 257-262.doi: 10.4251/wjgo.v3.i1.14. PMID: 21267399.
  15. Barbaryan A, Ali AM, Kwatra SG, et al. Primary diffuse large B-cell lymphoma of the ascending colon. Rare Tumors. 2013;5(2):85-88.doi: 10.4081/rt.2013.e23. PMID: 23888223.
  16. Haddad I, El Kurdi B, El Iskandarani M, Babar S, Young M. Primary Diffuse Large B-cell Lymphoma of the Sigmoid Colon. Cureus. 2019;11(6):e5048.doi: 10.7759/cureus.5048
  17. Thirunavukarasu P, Sathaiah M, Singla S,  Sukumar S,  Karunamurthy A, Kenneth K.W. Lee,  Zeh H, . Kane KM,Bartlett DL,et al. Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol 2010;37:901-7.doi: 10.3892/ijo_00000741. PMID: 20811712
  18. Knox RD, Luey N, Sioson L,  Kedziora A,  Clarkson A,  Watson N,  Toon CW,  Cussigh C,  Pincott S,  Pillinger S,  Salama Y,  Evans J,  Percy J, Schnitzler M,  Engel A,  Gill  AJ, et al. Medullary colorectal carcinoma revisited: a clinical and pathological study of 102 cases. Ann Surg Oncol. 2015;22:2988-96.
  19. Khalid U, Saleem T, Imam AM, Khan MR. Pathogenesis, diagnosis and management of primary melanoma of the colon. World J Surg Oncol. 2011;9:14.
  20. Kelly P, Zagars GK, Cormier JN, Ross MI, Guadagnolo AB.Sphincter-Sparing Local Excision and Hypofractionated Radiation Therapy for Anorectal Melanoma. Cancer 2011;117:4747–4755
  21. Row D, Weiser MR. Anorectal melanoma. Clin Colon Rectal Surg. 2009;22(2):120-126.doi: 10.1055/s-0029-1223844 . PMID: 20436837
  22. Yeh J J, Weiser M R, Shia J, Hwu W J. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005;6(6):438–439.doi: 10.1016/S1470-2045(05)70212-6. PMID: 15925823